Expect strong sales in 2023 driven by the US approval of zanubrutinib in CLL 4Q22 miss; 5 new models in the next 5 months Gradual revenue and margin recovery in FY23 调整2023-24E预测及目标价；维持“持有”评级 Evolving to a self-sustained business model 首次实现全年运营盈利，原创内容生产进入良性循环 年报点评报告：单季实现盈利 市场份额有望持续扩大 运营端降本提质成效显著，驶入“冷静增长”新航道 AI云业务、AI汽车业务引领公司成长 英伟达2022Q4财报点评